Literature DB >> 16928897

Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.

Haoyu Zeng1, Irina M Lozinskaya, Zuojun Lin, Robert N Willette, David P Brooks, Xiaoping Xu.   

Abstract

Human ether-a-go-go-related gene (hERG) encodes a rapidly activating delayed rectifier potassium channel that plays important roles in cardiac action potential repolarization. Although many drugs and compounds block hERG channels, activators of the channel have only recently been described. Three structurally diverse synthetic compounds have been reported to activate hERG channels by altering deactivation or inactivation or by unidentified mechanisms. Here, we describe a novel, naturally occurring hERG channel activator, mallotoxin (MTX). The effects of MTX on hERG channels were investigated using the patch-clamp technique. MTX increased both step and tail hERG currents with EC(50) values of 0.34 and 0.52 microM, respectively. MTX leftward shifted the voltage dependence of hERG channel activation to less depolarized voltages ( approximately 24 mV at 2.5 microM). In addition, MTX increased hERG deactivation time constants. MTX did not change the half-maximal inactivation voltage of the hERG channel, but it reduced the slope of the voltage-dependent inactivation curve. All of these factors contribute to the enhanced activity of hERG channels. During a voltage-clamp protocol using prerecorded cardiac action potentials, 2.5 microM MTX increased the total potassium ions passed through hERG channels by approximately 5-fold. In conclusion, MTX activates hERG channels through distinct mechanisms and with significantly higher potency than previously reported hERG channel activators.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928897     DOI: 10.1124/jpet.106.110593

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

Review 2.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

3.  Concatenated hERG1 tetramers reveal stoichiometry of altered channel gating by RPR-260243.

Authors:  Wei Wu; Alison Gardner; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2014-12-17       Impact factor: 4.436

Review 4.  Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects.

Authors:  Kai-ping Zhang; Bao-feng Yang; Bao-xin Li
Journal:  Acta Pharmacol Sin       Date:  2014-11-24       Impact factor: 6.150

5.  Modulation of Kv 11.1 (hERG) channels by 5-(((1H-indazol-5-yl)oxy)methyl)-N-(4-(trifluoromethoxy)phenyl)pyrimidin-2-amine (ITP-2), a novel small molecule activator.

Authors:  Harinath Sale; Samrat Roy; Jayakumar Warrier; Srinivasan Thangathirupathy; Yoganand Vadari; Shruthi K Gopal; Prasad Krishnamurthy; Manjunath Ramarao
Journal:  Br J Pharmacol       Date:  2017-06-18       Impact factor: 8.739

6.  Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations.

Authors:  Matthew D Perry; Chai Ann Ng; Kevin Phan; Erikka David; Kieran Steer; Mark J Hunter; Stefan A Mann; Mohammad Imtiaz; Adam P Hill; Ying Ke; Jamie I Vandenberg
Journal:  J Physiol       Date:  2016-05-27       Impact factor: 5.182

7.  A differential role for macropinocytosis in mediating entry of the two forms of vaccinia virus into dendritic cells.

Authors:  Kerrie J Sandgren; John Wilkinson; Monica Miranda-Saksena; Gerald M McInerney; Karen Byth-Wilson; Phillip J Robinson; Anthony L Cunningham
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

Review 8.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

9.  The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism.

Authors:  Guido Gessner; Regina Macianskiene; John G Starkus; Roland Schönherr; Stefan H Heinemann
Journal:  Eur J Pharmacol       Date:  2010-01-25       Impact factor: 4.432

10.  Ginsenoside Rg3, a Gating Modifier of EAG Family K+ Channels.

Authors:  Wei Wu; Alison Gardner; Frank B Sachse; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2016-08-08       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.